CoChat

Cushing's syndrome: Overview of clinical presentation, diagnostic tools and complications

Barbot, Mattia, Zilio, Marialuisa, Scaroni, Carla · 2020 · Best Practice & Research Clinical Endocrinology & Metabolism
Cited by 116

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

Cushing's syndrome (CS) is a severe condition that results from chronic exposure to elevated circulating cortisol levels; it is a rare but potentially life-threating condition, especially when not timely diagnosed and treated. Even though the diagnosis can be straightforward in florid cases due to their typical phenotype, milder forms can be missed. Despite the availability of different screening tests, the diagnosis remains challenging as none of the available tools proved to be fully accurate. Due to the ubiquitous effect of cortisol, it is easy understandable that its excess leads to a variety of systemic complications including hypertension, metabolic syndrome, bone damages and neurocognitive impairment. This article discusses clinical presentation of CS with an eye on the most frequent cortisol-related comorbidities and discuss the main pitfalls of first- and second-line tests in endogenous hypercortisolism diagnostic workup.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.beem.2020.101380

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Research works printed but not linked: 174

  1. Miljic, 2012, Pathogenesis of vascular complications in Cushing's syndrome, Horm Athens Greece, 11, 21, 10.1007/BF03401535 · DOI
  2. Lindholm, 2001, Incidence and late prognosis of cushing's syndrome: a population-based study, J Clin Endocrinol Metab, 86, 117
  3. Boscaro, 2009, Approach to the patient with possible Cushing's syndrome, J Clin Endocrinol Metab, 94, 3121, 10.1210/jc.2009-0612 · DOI · Paper page
  4. Ragnarsson, 2019, The incidence of Cushing's disease: a nationwide Swedish study, Pituitary, 22, 179, 10.1007/s11102-019-00951-1 · DOI · Paper page
  5. Tirosh, 2018, Genetics of micronodular adrenal hyperplasia and Carney complex, Presse Medicale Paris Fr 1983, 47, e127
  6. Lodish, 2018, Cushing's syndrome in pediatrics: an update, Endocrinol Metab Clin N Am, 47, 451, 10.1016/j.ecl.2018.02.008 · DOI · Paper page
  7. Lacroix, 2015, Cushing's syndrome, Lancet Lond Engl, 386, 913, 10.1016/S0140-6736(14)61375-1 · DOI · Paper page
  8. Monteiro, 2019, Adrenal carcinoma IN children: longitudinal study IN minas gerais, Brazil, Rev Paul Pediatr Orgao Of Soc Pediatr Sao Paulo, 37, 20, 10.1590/1984-0462/;2019;37;1;00002 · DOI
  9. Nieman, 2015, Cushing's Syndrome: update on signs, symptoms and biochemical screening, Eur J Endocrinol Eur Fed Endocr Soc, 173, 10.1530/EJE-15-0464 · DOI · Paper page
  10. Storr, 2007, Paediatric Cushing's syndrome: epidemiology, investigation and therapeutic advances, Trends Endocrinol Metab TEM, 18, 167, 10.1016/j.tem.2007.03.005 · DOI
  11. Barbot, 2019, The pathophysiology and treatment of hypertension in patients with cushing's syndrome, Front Endocrinol, 10, 321, 10.3389/fendo.2019.00321 · DOI
  12. Davi, 2017, Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study, Eur J Endocrinol, 176, 453, 10.1530/EJE-16-0809 · DOI
  13. Colao, 1999, Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure, J Clin Endocrinol Metab, 84, 2664
  14. Akaza, 2010, Endothelial dysfunction associated with hypercortisolism is reversible in Cushing's syndrome, Endocr J, 57, 245, 10.1507/endocrj.K09E-260 · DOI
  15. Fallo, 2009, Cardiovascular autonomic function in Cushing's syndrome, J Endocrinol Invest, 32, 41, 10.1007/BF03345677 · DOI
  16. Takagi, 2009, Hypokalemia, diabetes mellitus, and hypercortisolemia are the major contributing factors to cardiac dysfunction in adrenal Cushing's syndrome, Endocr J, 56, 1009, 10.1507/endocrj.K09E-198 · DOI
  17. Carrasco, 2012, Reproducibility and performance of one or two samples of salivary cortisol in the diagnosis of Cushing's syndrome using an automated immunoassay system, Endocrine, 41, 487, 10.1007/s12020-012-9597-z · DOI · Paper page
  18. Petersenn, 2014, High variability in baseline urinary free cortisol values in patients with Cushing's disease, Clin Endocrinol, 80, 261, 10.1111/cen.12259 · DOI · Paper page
  19. Dekker, 2012, The effect of common genetic variation in 11β-hydroxysteroid dehydrogenase type 1 on hypothalamic-pituitary-adrenal axis activity and incident depression, J Clin Endocrinol Metab, 97, E233, 10.1210/jc.2011-0601 · DOI · Paper page
  20. DeRijk, 2006, A common polymorphism in the mineralocorticoid receptor modulates stress responsiveness, J Clin Endocrinol Metab, 91, 5083, 10.1210/jc.2006-0915 · DOI · Paper page
  21. Løvås, 2009, Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone, Eur J Endocrinol, 160, 993, 10.1530/EJE-08-0880 · DOI · Paper page
  22. Martinez, 2009, Association of a mineralocorticoid receptor gene polymorphism with hypertension in a Spanish population, Am J Hypertens, 22, 649, 10.1038/ajh.2009.39 · DOI
  23. Ragnarsson, 2014, Common genetic variants in the glucocorticoid receptor and the 11β-hydroxysteroid dehydrogenase type 1 genes influence long-term cognitive impairments in patients with Cushing's syndrome in remission, J Clin Endocrinol Metab, 99, E1803, 10.1210/jc.2014-1906 · DOI · Paper page
  24. Valassi, 2017, A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome, Clin Endocrinol, 87, 433, 10.1111/cen.13414 · DOI
  25. Boscaro, 2001, Cushing's syndrome, Lancet Lond Engl, 357, 783, 10.1016/S0140-6736(00)04172-6 · DOI · Paper page
  26. Bansal, 2015, Pitfalls in the diagnosis and management of Cushing's syndrome, Neurosurg Focus, 38, E4, 10.3171/2014.11.FOCUS14704 · DOI · Paper page
  27. Ceccato, 2015, Screening tests for cushing's syndrome: urinary free cortisol role measured by LC-MS/MS, J Clin Endocrinol Metab, 100, 3856, 10.1210/jc.2015-2507 · DOI · Paper page
  28. Alexandraki, 2009, The prevalence and characteristic features of cyclicity and variability in Cushing's disease, Eur J Endocrinol, 160, 1011, 10.1530/EJE-09-0046 · DOI · Paper page
  29. Atkinson, 2011, What is the best approach to suspected cyclical Cushing syndrome? Strategies for managing Cushing's syndrome with variable laboratory data, Clin Endocrinol, 75, 27, 10.1111/j.1365-2265.2011.04033.x · DOI · Paper page
  30. Boscaro, 2000, The diagnosis of Cushing's syndrome: atypical presentations and laboratory shortcomings, Arch Intern Med, 160, 3045, 10.1001/archinte.160.20.3045 · DOI · Paper page
  31. Meikle, 2003, Pseudo-Cushing syndrome caused by fenofibrate interference with urinary cortisol assayed by high-performance liquid chromatography, J Clin Endocrinol Metab, 88, 3521, 10.1210/jc.2003-030234 · DOI · Paper page
  32. Turpeinen, 1997, Determination of urinary free cortisol by HPLC, Clin Chem, 43, 1386, 10.1093/clinchem/43.8.1386 · DOI · Paper page
  33. Ceccato, 2014, The diagnostic performance of urinary free cortisol is better than the cortisol:cortisone ratio in detecting de novo Cushing's syndrome: the use of a LC-MS/MS method in routine clinical practice, Eur J Endocrinol, 171, 1, 10.1530/EJE-14-0061 · DOI · Paper page
  34. Aranda, 2016, Accuracy of immunoassay and mass spectrometry urinary free cortisol in the diagnosis of Cushing's syndrome, Pituitary, 19, 496, 10.1007/s11102-016-0730-5 · DOI
  35. Pappachan, 2017, Cushing's syndrome: a practical approach to diagnosis and differential diagnoses, J Clin Pathol, 70, 350, 10.1136/jclinpath-2016-203933 · DOI · Paper page
  36. Raff, 1998, Late-night salivary cortisol as a screening test for Cushing's syndrome, J Clin Endocrinol Metab, 83, 2681
  37. Raff, 2012, Cushing's syndrome: diagnosis and surveillance using salivary cortisol, Pituitary, 15, 64, 10.1007/s11102-011-0333-0 · DOI
  38. Graham, 2013, A comparison of the use of urinary cortisol to creatinine ratios and nocturnal salivary cortisol in the evaluation of cyclicity in patients with Cushing's syndrome, J Clin Endocrinol Metab, 98, E72, 10.1210/jc.2012-2925 · DOI · Paper page
  39. Chiodini, 2017, Six controversial issues on subclinical Cushing's syndrome, Endocrine, 56, 262, 10.1007/s12020-016-1017-3 · DOI
  40. Masjkur, 2019, Plasma steroid profiles in subclinical compared with overt adrenal cushing syndrome, J Clin Endocrinol Metab, 104, 4331, 10.1210/jc.2018-02349 · DOI · Paper page
  41. Terzolo, 2011, AME position statement on adrenal incidentaloma, Eur J Endocrinol, 164, 851, 10.1530/EJE-10-1147 · DOI · Paper page
  42. Talbot, 2003, Analytical and clinical aspects of adrenocorticotrophin determination, Ann Clin Biochem, 40, 453, 10.1258/000456303322326371 · DOI · Paper page
  43. Barbot, 2016, Second-line tests in the differential diagnosis of ACTH-dependent Cushing's syndrome, Pituitary, 19, 488, 10.1007/s11102-016-0729-y · DOI
  44. Newell-Price, 2002, Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome, J Clin Endocrinol Metab, 87, 1640
  45. Nieman, 1993, A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome, J Clin Endocrinol Metab, 77, 1308
  46. Ritzel, 2015, ACTH after 15 min distinguishes between Cushing's disease and ectopic Cushing's syndrome: a proposal for a short and simple CRH test, Eur J Endocrinol, 173, 197, 10.1530/EJE-14-0912 · DOI · Paper page
  47. al-Saadi, 1998, A very high dose dexamethasone suppression test for differential diagnosis of Cushing's syndrome, Clin Endocrinol, 48, 45, 10.1046/j.1365-2265.1998.00345.x · DOI
  48. Aron, 1997, Effectiveness versus efficacy: the limited value in clinical practice of high dose dexamethasone suppression testing in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome, J Clin Endocrinol Metab, 82, 1780
  49. Avgerinos, 1994, The metyrapone and dexamethasone suppression tests for the differential diagnosis of the adrenocorticotropin-dependent Cushing syndrome: a comparison, Ann Intern Med, 121, 318, 10.7326/0003-4819-121-5-199409010-00002 · DOI · Paper page
  50. Aytug, 2012, Assessment of the utility of the high-dose dexamethasone suppression test in confirming the diagnosis of Cushing disease, Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol, 18, 152
  51. Bruno, 1985, Nocturnal high-dose dexamethasone suppression test in the aetiological diagnosis of Cushing's syndrome, Acta Endocrinol, 109, 158
  52. Dichek, 1994, A comparison of the standard high dose dexamethasone suppression test and the overnight 8-mg dexamethasone suppression test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome, J Clin Endocrinol Metab, 78, 418, 10.1210/jcem.78.2.8106630 · doi:10.1210/jcem.78.2.8106630 · Paper page
  53. Flack, 1992, Urine free cortisol in the high-dose dexamethasone suppression test for the differential diagnosis of the Cushing syndrome, Ann Intern Med, 116, 211, 10.7326/0003-4819-116-3-211 · DOI · Paper page
  54. Grossman, 1988, CRF in the differential diagnosis of Cushing's syndrome: a comparison with the dexamethasone suppression test, Clin Endocrinol, 29, 167, 10.1111/j.1365-2265.1988.tb00258.x · DOI · Paper page
  55. Hermus, 1986, The corticotropin-releasing-hormone test versus the high-dose dexamethasone test in the differential diagnosis of Cushing's syndrome, Lancet Lond Engl, 2, 540, 10.1016/S0140-6736(86)90113-3 · DOI
  56. Liddle, 1960, Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome, J Clin Endocrinol Metab, 20, 1539, 10.1210/jcem-20-12-1539 · DOI · Paper page
  57. Midgette, 1995, High-dose dexamethasone suppression testing versus inferior petrosal sinus sampling in the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome: a decision analysis, Am J Med Sci, 309, 162, 10.1097/00000441-199503000-00007 · DOI
  58. Rossi, 1996, [Night suppression with high doses of dexamethasone and metyrapone tests for the etiological diagnosis of Cushing syndrome], Medicina, 56, 455
  59. Sriussadaporn, 1996, Nocturnal 8 mg dexamethasone suppression test: a practical and accurate test for identification of the cause of endogenous Cushing's syndrome, Br J Clin Pract, 50, 9, 10.1111/j.1742-1241.1996.tb10010.x · DOI
  60. Tyrrell, 1986, An overnight high-dose dexamethasone suppression test for rapid differential diagnosis of Cushing's syndrome, Ann Intern Med, 104, 180, 10.7326/0003-4819-104-2-180 · DOI · Paper page
  61. van den Bogaert, 1999, The continuous 7-hour intravenous dexamethasone suppression test in the differential diagnosis of ACTH-dependent Cushing's syndrome, Clin Endocrinol, 51, 193, 10.1046/j.1365-2265.1999.00759.x · DOI
  62. Vilar, 2007, [Endogenous Cushing's syndrome: clinical and laboratorial features in 73 cases], Arq Bras Endocrinol Metabol, 51, 566, 10.1590/S0004-27302007000400010 · DOI
  63. Isidori, 2003, Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome, J Clin Endocrinol Metab, 88, 5299, 10.1210/jc.2003-030510 · DOI · Paper page
  64. Nieman, 1986, The ovine corticotropin-releasing hormone stimulation test and the dexamethasone suppression test in the differential diagnosis of Cushing's syndrome, Ann Intern Med, 105, 862, 10.7326/0003-4819-105-6-862 · DOI · Paper page
  65. Tsagarakis, 2002, The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent cushing's syndrome: constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion, J Clin Endocrinol Metab, 87, 1646
  66. Kola, 2008, Dynamic testing in Cushing's syndrome, Pituitary, 11, 155, 10.1007/s11102-007-0079-x · DOI
  67. Colombo, 1994, MR of corticotropin-secreting pituitary microadenomas, AJNR Am J Neuroradiol, 15, 1591
  68. Vitale, 2017, Pituitary magnetic resonance imaging in Cushing's disease, Endocrine, 55, 691, 10.1007/s12020-016-1038-y · DOI
  69. Chowdhury, 2010, A change in pituitary magnetic resonance imaging protocol detects ACTH-secreting tumours in patients with previously negative results, Clin Endocrinol, 72, 502, 10.1111/j.1365-2265.2009.03646.x · DOI · Paper page
  70. Erickson, 2010, 3 Tesla magnetic resonance imaging with and without corticotropin releasing hormone stimulation for the detection of microadenomas in Cushing's syndrome, Clin Endocrinol, 72, 793, 10.1111/j.1365-2265.2009.03723.x · DOI
  71. Fukuhara, 2019, Outcomes of three-Tesla magnetic resonance imaging for the identification of pituitary adenoma in patients with Cushing's disease, Endocr J, 66, 259, 10.1507/endocrj.EJ18-0458 · DOI
  72. Grober, 2018, Comparison of MRI techniques for detecting microadenomas in Cushing's disease, J Neurosurg, 128, 1051
  73. Kasaliwal, 2013, Volume interpolated 3D-spoiled gradient echo sequence is better than dynamic contrast spin echo sequence for MRI detection of corticotropin secreting pituitary microadenomas, Clin Endocrinol, 78, 825, 10.1111/cen.12069 · DOI · Paper page
  74. Tabarin, 1998, Comparative evaluation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of Cushing's disease, Clin Endocrinol, 49, 293, 10.1046/j.1365-2265.1998.00541.x · DOI · Paper page
  75. Cristante, 2019, Why we should still treat by neurosurgery patients with Cushing's disease and a normal or inconclusive pituitary MRI, J Clin Endocrinol Metab, 10.1210/jc.2019-00333 · DOI · Paper page
  76. Losa, 2019, Bilateral inferior petrosal sinus sampling in adrenocorticotropin-dependent hypercortisolism: always, never, or sometimes?, J Endocrinol Invest, 10.1007/s40618-019-1006-5 · DOI
  77. Findling, 2004, Identification of patients with Cushing's disease with negative pituitary adrenocorticotropin gradients during inferior petrosal sinus sampling: prolactin as an index of pituitary venous effluent, J Clin Endocrinol Metab, 89, 6005, 10.1210/jc.2004-1378 · DOI · Paper page
  78. Bonelli, 1999, Venous subarachnoid hemorrhage after inferior petrosal sinus sampling for adrenocorticotropic hormone, AJNR Am J Neuroradiol, 20, 306
  79. Lefournier, 1999, One transient neurological complication (sixth nerve palsy) in 166 consecutive inferior petrosal sinus samplings for the etiological diagnosis of Cushing's syndrome, J Clin Endocrinol Metab, 84, 3401
  80. Obuobie, 2000, Venous thrombo-embolism following inferior petrosal sinus sampling in Cushing's disease, J Endocrinol Invest, 23, 542, 10.1007/BF03343772 · DOI
  81. Castinetti, 2007, Desmopressin test during petrosal sinus sampling: a valuable tool to discriminate pituitary or ectopic ACTH-dependent Cushing's syndrome, Eur J Endocrinol, 157, 271, 10.1530/EJE-07-0215 · DOI · Paper page
  82. Tsagarakis, 2007, J Clin Endocrinol Metab, 92, 10.1210/jc.2006-2691 · DOI · Paper page
  83. Chen, 2019, The effects of sampling lateralization on bilateral inferior petrosal sinus sampling and desmopressin stimulation test for pediatric Cushing's disease, Endocrine, 63, 582, 10.1007/s12020-018-1779-x · DOI
  84. Deipolyi, 2017, Bilateral inferior petrosal sinus sampling: experience in 327 patients, J Neurointerventional Surg, 9, 196, 10.1136/neurintsurg-2015-012164 · DOI
  85. Feng, 2018, Tumour lateralization in Cushing's disease by inferior petrosal sinus sampling with desmopressin, Clin Endocrinol, 88, 251, 10.1111/cen.13505 · DOI
  86. Pereira, 2019, Diagnostic accuracy of bilateral inferior petrosal sinus sampling: the experience of a tertiary centre, Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc
  87. Wind, 2013, The lateralization accuracy of inferior petrosal sinus sampling in 501 patients with Cushing's disease, J Clin Endocrinol Metab, 98, 2285, 10.1210/jc.2012-3943 · DOI · Paper page
  88. Isidori, 2015, The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications, J Hypertens, 33, 44, 10.1097/HJH.0000000000000415 · DOI · Paper page
  89. Isidori, 2015, Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect, Eur J Endocrinol, 173, R101, 10.1530/EJE-15-0308 · DOI
  90. Pivonello, 2016, Complications of Cushing's syndrome: state of the art, Lancet Diabetes Endocrinol, 4, 611, 10.1016/S2213-8587(16)00086-3 · DOI · Paper page
  91. Magiakou, 1997, Blood pressure in children and adolescents with Cushing's syndrome before and after surgical care, J Clin Endocrinol Metab, 82, 1734
  92. Pecori Giraldi, 2007, Circadian blood pressure profile in patients with active Cushing's disease and after long-term cure, Horm Metab Res Horm Stoffwechselforschung Horm Metab, 39, 908, 10.1055/s-2007-992813 · DOI
  93. Magiakou, 2006, Hypertension in Cushing's syndrome, Best Pract Res Clin Endocrinol Metabol, 20, 467, 10.1016/j.beem.2006.07.006 · DOI
  94. Kirilov, 2003, Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome, Eur J Endocrinol, 149, 549, 10.1530/eje.0.1490549 · DOI · Paper page
  95. Kelly, 2000, Role of erythropoietin in cortisol-induced hypertension, J Hum Hypertens, 14, 195, 10.1038/sj.jhh.1000959 · DOI
  96. Pirpiris, 1992, Pressor responsiveness in corticosteroid-induced hypertension in humans, Hypertens Dallas Tex 1979, 19, 567
  97. Wallerath, 1999, Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension, Proc Natl Acad Sci U S A, 96, 13357, 10.1073/pnas.96.23.13357 · DOI · Paper page
  98. Kamenický, 2014, Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging study, J Clin Endocrinol Metab, 99, E2144, 10.1210/jc.2014-1783 · DOI · Paper page
  99. Muiesan, 2003, Left ventricular structural and functional characteristics in Cushing's syndrome, J Am Coll Cardiol, 41, 2275, 10.1016/S0735-1097(03)00493-5 · DOI · Paper page
  100. Toja, 2012, Clinical relevance of cardiac structure and function abnormalities in patients with Cushing's syndrome before and after cure, Clin Endocrinol, 76, 332, 10.1111/j.1365-2265.2011.04206.x · DOI
  101. Ainscough, 2009, Angiotensin II type-1 receptor activation in the adult heart causes blood pressure-independent hypertrophy and cardiac dysfunction, Cardiovasc Res, 81, 592, 10.1093/cvr/cvn230 · DOI
  102. Brilla, 1992, Mineralocorticoid excess, dietary sodium, and myocardial fibrosis, J Lab Clin Med, 120, 893
  103. Pecori Giraldi, 2011, High prevalence of prolonged QT interval duration in male patients with Cushing's disease, Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc, 119, 221, 10.1055/s-0031-1271628 · DOI
  104. Chandran, 2013, Decreased autonomic modulation of heart rate and altered cardiac sympathovagal balance in patients with Cushing's syndrome: role of endogenous hypercortisolism, Neuroendocrinology, 97, 309, 10.1159/000345905 · DOI
  105. Albiger, 2006, Patients with Cushing's syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors, Horm Metab Res Horm Stoffwechselforschung Horm Metab, 38, 405, 10.1055/s-2006-944545 · DOI
  106. Baykan, 2007, Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing's Syndrome, Endocrine, 31, 300, 10.1007/s12020-007-0033-8 · DOI
  107. Duprez, 2006, Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review, J Hypertens, 24, 983, 10.1097/01.hjh.0000226182.60321.69 · DOI · Paper page
  108. Rizzoni, 2006, Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism, J Clin Endocrinol Metab, 91, 2638, 10.1210/jc.2006-0101 · DOI · Paper page
  109. Barahona, 2013, Coronary artery disease detected by multislice computed tomography in patients after long-term cure of Cushing's syndrome, J Clin Endocrinol Metab, 98, 1093, 10.1210/jc.2012-3547 · DOI · Paper page
  110. Neary, 2013, Hypercortisolism is associated with increased coronary arterial atherosclerosis: analysis of noninvasive coronary angiography using multidetector computerized tomography, J Clin Endocrinol Metab, 98, 2045, 10.1210/jc.2012-3754 · DOI · Paper page
  111. Debono, 2016, Cushing's syndrome: where and how to find it, Front Horm Res, 46, 15, 10.1159/000443861 · DOI
  112. Ferraù, 2018, Metabolic syndrome in cushing's syndrome patients, Front Horm Res, 49, 85, 10.1159/000486002 · DOI
  113. Geer, 2012, Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI, J Clin Endocrinol Metab, 97, 1702, 10.1210/jc.2011-3123 · DOI · Paper page
  114. Geer, 2010, MRI assessment of lean and adipose tissue distribution in female patients with Cushing's disease, Clin Endocrinol, 73, 469, 10.1111/j.1365-2265.2010.03829.x · DOI
  115. Berthon, 2014, A systematic review of the effect of oral glucocorticoids on energy intake, appetite, and body weight in humans, Nutr Res Newsl N, 34, 179, 10.1016/j.nutres.2013.12.006 · DOI
  116. Castonguay, 1991, Glucocorticoids as modulators in the control of feeding, Brain Res Bull, 27, 423, 10.1016/0361-9230(91)90136-8 · DOI
  117. Tataranni, 1996, Effects of glucocorticoids on energy metabolism and food intake in humans, Am J Physiol, 271, E317
  118. Pivonello, 2014, Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study, Clin Endocrinol, 81, 408, 10.1111/cen.12431 · DOI · Paper page
  119. Pivonello, 2009, The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery, J Clin Endocrinol Metab, 94, 223, 10.1210/jc.2008-1533 · DOI · Paper page
  120. Friedman, 1996, Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM, Endocr J, 43, 645, 10.1507/endocrj.43.645 · DOI · Paper page
  121. Barbot, 2018, Diabetes mellitus secondary to cushing's disease, Front Endocrinol, 9, 284, 10.3389/fendo.2018.00284 · DOI · Paper page
  122. Bodine, 2015, Glucocorticoids and skeletal muscle, Adv Exp Med Biol, 872, 145, 10.1007/978-1-4939-2895-8_7 · DOI · Paper page
  123. Kuo, 2013, Metabolic functions of glucocorticoid receptor in skeletal muscle, Mol Cell Endocrinol, 380, 79, 10.1016/j.mce.2013.03.003 · DOI · Paper page
  124. Eriksen, 2015, Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance, Diabetologia, 58, 920, 10.1007/s00125-015-3522-y · DOI
  125. Brennan-Speranza, 2012, Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism, J Clin Invest, 122, 4172, 10.1172/JCI63377 · DOI · Paper page
  126. Oldknow, 2015, Endocrine role of bone: recent and emerging perspectives beyond osteocalcin, J Endocrinol, 225, R1, 10.1530/JOE-14-0584 · DOI · Paper page
  127. Bernal-Mizrachi, 2007, An afferent vagal nerve pathway links hepatic PPARalpha activation to glucocorticoid-induced insulin resistance and hypertension, Cell Metabol, 5, 91, 10.1016/j.cmet.2006.12.010 · DOI
  128. Yi, 2012, Glucocorticoid signaling in the arcuate nucleus modulates hepatic insulin sensitivity, Diabetes, 61, 339, 10.2337/db11-1239 · DOI · Paper page
  129. Geelen, 2013, BclI glucocorticoid receptor polymorphism is associated with greater body fatness: the Hoorn and CODAM studies, J Clin Endocrinol Metab, 98, E595, 10.1210/jc.2012-3442 · DOI · Paper page
  130. Moreira, 2013, Modulatory effect of BclI GR gene polymorphisms on the obesity phenotype in Brazilian patients with Cushing's disease, Clin Sao Paulo Braz, 68, 579, 10.6061/clinics/2013(05)01 · DOI
  131. Webb, 2010, Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma, J Clin Endocrinol Metab, 95, 630, 10.1210/jc.2009-0806 · DOI · Paper page
  132. Jeffcoate, 1977, Metyrapone in long-term management of Cushing's disease, Br Med J, 2, 215, 10.1136/bmj.2.6081.215 · DOI · Paper page
  133. Henry, 2013, Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers, J Clin Endocrinol Metab, 98, 3446, 10.1210/jc.2013-1771 · DOI · Paper page
  134. Munir, 2010, Management of diabetes mellitus in Cushing's syndrome, Neuroendocrinology, 92, 82, 10.1159/000314316 · DOI · Paper page
  135. Lambert, 2013, Predictors of mortality and long-term outcomes in treated Cushing's disease: a study of 346 patients, J Clin Endocrinol Metab, 98, 1022, 10.1210/jc.2012-2893 · DOI · Paper page
  136. Trementino, 2010, Coagulopathy in Cushing's syndrome, Neuroendocrinology, 92, 55, 10.1159/000314349 · DOI · Paper page
  137. Koutroumpi, 2014, Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth?, Pituitary, 17, 68, 10.1007/s11102-013-0467-3 · DOI
  138. Zilio, 2016, A venous thromboembolism risk assessment model for patients with Cushing's syndrome, Endocrine, 52, 322, 10.1007/s12020-015-0665-z · DOI
  139. Barbot, 2015, Perioperative thromboprophylaxis in Cushing's disease: what we did and what we are doing?, Pituitary, 18, 487, 10.1007/s11102-014-0600-y · DOI
  140. Erem, 2009, Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels, J Endocrinol Invest, 32, 169, 10.1007/BF03345709 · DOI
  141. Patrassi, 1992, The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state, Blood Coagul Fibrinolysis Int J Haemost Thromb, 3, 789, 10.1097/00001721-199212000-00013 · DOI · Paper page
  142. Kastelan, 2009, Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers, Endocrine, 36, 70, 10.1007/s12020-009-9186-y · DOI
  143. Manetti, 2010, Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery, Eur J Endocrinol, 163, 783, 10.1530/EJE-10-0583 · DOI · Paper page
  144. Casonato, 1999, Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome, Blood Coagul Fibrinolysis Int J Haemost Thromb, 10, 145, 10.1097/00001721-199904000-00006 · DOI · Paper page
  145. Barbot, 2018, Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease, Endocrine, 62, 207, 10.1007/s12020-018-1669-2 · DOI
  146. van der Pas, 2012, The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy, J Clin Endocrinol Metab, 97, 1303, 10.1210/jc.2011-2753 · DOI · Paper page
  147. Kaltsas, 2002, Osteoporosis in Cushing's syndrome, Front Horm Res, 30, 60, 10.1159/000061073 · DOI
  148. Manelli, 2000, Glucocorticoid-induced osteoporosis, Trends Endocrinol Metab TEM, 11, 79, 10.1016/S1043-2760(00)00234-4 · DOI
  149. Minetto, 2004, Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, 15, 855, 10.1007/s00198-004-1616-3 · DOI
  150. Tauchmanovà, 2006, Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status, J Clin Endocrinol Metab, 91, 1779, 10.1210/jc.2005-0582 · DOI · Paper page
  151. Di Somma, 2002, Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease, Clin Endocrinol, 56, 153, 10.1046/j.0300-0664.2001.01454.doc.x · DOI · Paper page
  152. Canalis, 2001, Glucocorticoid-induced osteoporosis: summary of a workshop, J Clin Endocrinol Metab, 86, 5681, 10.1210/jcem.86.12.8066 · DOI · Paper page
  153. Seibel, 2013, Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives, Lancet Diabetes Endocrinol, 1, 59, 10.1016/S2213-8587(13)70045-7 · DOI · Paper page
  154. Weinstein, 2011, Clinical practice. Glucocorticoid-induced bone disease, N Engl J Med, 365, 62, 10.1056/NEJMcp1012926 · DOI · Paper page
  155. Rubin, 2002, Clinical review 151: the role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence, J Clin Endocrinol Metab, 87, 4033, 10.1210/jc.2002-012101 · DOI · Paper page
  156. Di Somma, 1998, Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease, Clin Endocrinol, 48, 655, 10.1046/j.1365-2265.1998.00486.x · DOI · Paper page
  157. Lane, 2000, Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial, J Bone Miner Res Off J Am Soc Bone Miner Res, 15, 944, 10.1359/jbmr.2000.15.5.944 · DOI · Paper page
  158. Scillitani, 2014, Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, 25, 441, 10.1007/s00198-013-2588-y · DOI · Paper page
  159. Kristo, 2006, Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study, Eur J Endocrinol, 154, 109, 10.1530/eje.1.02067 · DOI · Paper page
  160. Pivonello, 2015, Neuropsychiatric disorders in Cushing's syndrome, Front Neurosci, 9, 129, 10.3389/fnins.2015.00129 · DOI · Paper page
  161. Sonino, 2001, Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment, CNS Drugs, 15, 361, 10.2165/00023210-200115050-00003 · DOI · Paper page
  162. Jeffcoate, 1979, Psychiatric manifestations of Cushing's syndrome: response to lowering of plasma cortisol, Q J Med, 48, 465
  163. Bourdeau, 2002, Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism, J Clin Endocrinol Metab, 87
  164. Forget, 2002, Persistent cognitive impairment following surgical treatment of Cushing's syndrome, Psychoneuroendocrinology, 27, 367, 10.1016/S0306-4530(01)00059-2 · DOI
  165. Bleicken, 2010, Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency, Clin Endocrinol, 72, 297, 10.1111/j.1365-2265.2009.03596.x · DOI · Paper page
  166. Minetto, 2011, Steroid myopathy: some unresolved issues, J Endocrinol Invest, 34, 370, 10.1007/BF03347462 · DOI
  167. Wajchenberg, 1995, Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease, J Clin Endocrinol Metab, 80, 2791
  168. Minetto, 2011, Do muscle fiber conduction slowing and decreased levels of circulating muscle proteins represent sensitive markers of steroid myopathy? A pilot study in Cushing's disease, Eur J Endocrinol, 164, 985, 10.1530/EJE-10-1169 · DOI
  169. Pereira, 2011, Glucocorticoid-induced myopathy, Jt Bone Spine Rev Rhum, 78, 41, 10.1016/j.jbspin.2010.02.025 · DOI · Paper page
  170. Arnaldi, 2012, Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications, J Endocrinol Invest, 35, 434, 10.1007/BF03345431 · DOI
  171. Valassi, 2019, High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry, Eur J Endocrinol, 181, 461, 10.1530/EJE-19-0464 · DOI · Paper page
  172. Ilias, 2005, Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health, J Clin Endocrinol Metab, 90, 4955, 10.1210/jc.2004-2527 · DOI · Paper page
  173. Sarlis, 2000, Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin, J Clin Endocrinol Metab, 85, 42
  174. Critchley, 2018, Glycemic control and risk of infections among people with type 1 or type 2 diabetes in a large primary care cohort study, Diabetes Care, 41, 2127, 10.2337/dc18-0287 · DOI · Paper page

Cited by

See all 116

Metadata

Authors
Barbot, M., Zilio, M., & Scaroni, C.
Venue
Best Practice & Research Clinical Endocrinology & Metabolism
Publisher
Elsevier BV
Published
2020-03
Volume
34
Issue
2
Pages
101380
ISSN
1521-690X (ISSN-L)
OpenAlex
W3003229257
Cited by
116
References
57
FWCI
10.99
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cushing's syndrome: Overview of clinical presentation, diagnostic tools and complications. https://app.cochat.ai/papers/10.1016/j.beem.2020.101380
The paper
Barbot, M., Zilio, M., & Scaroni, C. (2020). Cushing's syndrome: Overview of clinical presentation, diagnostic tools and complications. Best Practice & Research Clinical Endocrinology & Metabolism. https://doi.org/10.1016/j.beem.2020.101380

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.